scholarly journals Visualizing reactive astrogliosis extends survival in glioblastoma patients

2021 ◽  
Author(s):  
Hae Young Ko ◽  
Jee-In Chung ◽  
Dongwoo Kim ◽  
Yongmin Mason Park ◽  
Han Hee Jo ◽  
...  
Keyword(s):  
Glucose Transporter ◽  
Patient Survival ◽  
Gaba Release ◽  
Targeted Biopsy ◽  
Reactive Astrogliosis ◽  
Guided Surgery ◽  
Glioblastoma Patient ◽  
Acetate Uptake ◽  
Conventional Mri ◽  
Dismal Prognosis

ABSTRACTGlioblastoma is a devastating brain tumor with dismal prognosis of only 15-month survival regardless of surgical resection with few alternatives. Here, we report a reactive astrogliosis-targeted neuroimaging technique using the fusion of 11C-acetate PET and MRI (AcePET) extended the overall survival of patients by 5.25 months compared to conventional MRI-guided surgery. Targeted biopsy of 11C-acetate uptake-increased regions showed the signs of reactive astrogliosis with cancer stem cells at the boundary of high-grade gliomas. The appearance of marginal reactive astrogliosis and MCT1-dependent 11C-acetate uptake was recapitulated in U87MG-orthotophic models. U87MG-derived excessive glutamate caused reactive astrogliosis and aberrant astrocytic GABA-release, which subsequently reduced neuronal glucose uptake through glucose transporter-3 (GLUT3). We propose AcePET-guided surgery, visualizing reactive astrogliosis, as an advanced surgical strategy to improve glioblastoma patient survival.One-Sentence SummaryAcePET-guided surgery extends patient survival by visualizing reactive astrogliosis at the tumor margin

scholarly journals IMST-39. IDO1 IS PROGNOSTIC FOR GLIOBLASTOMA PATIENT SURVIVAL AND CENTRALLY CORRELATES WITH POTENTLY IMMUNOSUPPRESSIVE MEDIATORS

2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi95-vi95
Author(s):  
Lijie Zhai ◽  
Matthew Genet ◽  
Erik Ladomersky ◽  
Kristen Lauing ◽  
Meijing Wu ◽  
...  
Keyword(s):  
Patient Survival ◽  
Glioblastoma Patient

Abstract A064: IDO1 expression stratifies glioblastoma patient survival and correlates with dominantly immunosuppressive pathways

2016 ◽  
Author(s):  
Lijie Zhai ◽  
Matthew Genet ◽  
Erik Ladomersky ◽  
Kristen Lauing ◽  
Meijing Wu ◽  
...  
Keyword(s):  
Patient Survival ◽  
Glioblastoma Patient ◽  
Ido1 Expression

scholarly journals The Predictive and Diagnostic Potential of Symptoms for Glioblastoma Patient Survival

2021 ◽  
Author(s):  
Oliver Mrowczynski ◽  
Ae Lim Yang ◽  
Jason Liao ◽  
Sara Langan ◽  
Elias Rizk
Keyword(s):  
Early Diagnosis ◽  
Patient Survival ◽  
Memory Loss ◽  
Loss Of Consciousness ◽  
Tumor Biomarkers ◽  
Surgical Biopsy ◽  
Specific Patient ◽  
Non Invasive ◽  
Glioblastoma Patient ◽  
Diagnostic Potential

Abstract PurposeGlioblastoma is a devastating malignancy with a dismal survival rate and median survival time of 14 months. Currently, the biomarkers for glioblastoma are mostly molecular and include EGFRvIII, ATRX, PTEN, IDH1, MGMT, and others. These prognostic tumor biomarkers are obtained through a surgical biopsy and thus not easily attainable. Clinicians would benefit from a robust, non-invasive, and readily available indicator for early diagnosis and accurate prognostication for glioblastoma patients. MethodsIn this study, we assessed whether specific patient symptoms could provide early diagnosis of glioblastoma. Further, if any patient symptomatology would provide clinicians with the ability to prognosticate patient survival more accurately. We retrospectively reviewed the clinical data for 218 patients. We determined whether symptoms including headache, weakness, seizure, memory loss/confusion, visual changes, speech changes, and loss of consciousness led to a patient being diagnosed earlier and if any of these symptoms predicted a diminished patient survival. ResultsOur study determined that weakness and memory loss/confusion were symptoms that predicted diminished survival, and weakness alone was the symptom that predicted earlier diagnosis. Conclusion: This study further elucidates the complexities of glioblastoma and provides clinicians with more data for their patients when discussing prognostication after diagnosis of glioblastoma.

scholarly journals Fluorescence-Guided Surgery for Hepatoblastoma with Indocyanine Green

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1215 ◽  
Author(s):  
Yohei Yamada ◽  
Michinobu Ohno ◽  
Akihiro Fujino ◽  
Yutaka Kanamori ◽  
Rie Irie ◽  
...  
Keyword(s):  
Indocyanine Green ◽  
Patient Survival ◽  
Liver Tumors ◽  
Distant Metastases ◽  
Complete Resection ◽  
Hepatic Tumors ◽  
Primary Liver Tumors ◽  
Guided Surgery ◽  
Fluorescence Guided Surgery ◽  
Subsequent Patient

Fluorescence-guided surgery with indocyanine green (ICG) for malignant hepatic tumors has been gaining more attention with technical advancements. Since hepatoblastomas (HBs) possess similar features to hepatocellular carcinoma, fluorescence-guided surgery can be used for HBs, as aggressive surgical resection, even for distant metastases of HBs, often contributes positively to R0 (complete) resection and subsequent patient survival. Despite a few caveats, fluorescence-guided surgery allows for the more sensitive identification of lesions that may go undetected by conventional imaging or be invisible macroscopically. This leads to precise resection of distant metastatic tumors as well as primary liver tumors.

scholarly journals Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival

Oncotarget ◽  
2017 ◽  
Vol 8 (30) ◽  
pp. 50117-50123 ◽  
Author(s):  
Peng-Fei Wang ◽  
Hong-Wang Song ◽  
Hong-Qing Cai ◽  
Ling-Wei Kong ◽  
Kun Yao ◽  
...  
Keyword(s):  
Patient Survival ◽  
Idh Mutation ◽  
Inflammation Markers ◽  
Mutation Status ◽  
Glioblastoma Patient

The predictive potential of hyponatremia for glioblastoma patient survival

2018 ◽  
Vol 138 (1) ◽  
pp. 99-104 ◽  
Author(s):  
Oliver D. Mrowczynski ◽  
Alexandre J. Bourcier ◽  
Jason Liao ◽  
Sara T. Langan ◽  
Charles S. Specht ◽  
...  
Keyword(s):  
Patient Survival ◽  
Glioblastoma Patient
Sign in / Sign up

Export Citation Format

Share Document